Septic Cardiomyopathy

Area of Science:

• Cardiology
• Intensive Care Medicine
• Mitochondrial Biology

Background:

• Sepsis, a life-threatening response to infection, frequently leads to myocardial dysfunction.
• Septic cardiomyopathy, characterized by impaired heart contractility, affects 10-70% of sepsis patients.
• Mitochondrial dysfunction is a primary driver of septic cardiomyopathy, affecting energy metabolism and cellular processes.

Purpose of the Study:

• To review the pathophysiology and diagnosis of sepsis-induced myocardial dysfunction.
• To explore the role of mitochondrial dysfunction in septic cardiomyopathy.
• To discuss current and future therapeutic strategies for septic cardiomyopathy.

Main Methods:

• Review of existing literature on sepsis, myocardial dysfunction, and mitochondrial biology.
• Analysis of diagnostic methods including echocardiography and cardiac MRI.
• Examination of potential biomarkers such as FGF-21, GDF-15, and miRNA.

Main Results:

• Left ventricular diastolic dysfunction is a common early biomarker in septic shock.
• Right ventricular dysfunction is associated with a worse prognosis in sepsis patients.
• Biomarkers like FGF-21 and GDF-15 show potential but lack specificity in complex cases.

Conclusions:

• Mitochondrial dysfunction is central to septic cardiomyopathy's development.
• Echocardiography and advanced imaging aid diagnosis, though accessibility varies.
• Targeted therapies addressing mitochondrial mechanisms are needed for effective septic cardiomyopathy treatment.